Sage Therapeutics, after a year of disappointing readouts from its clinical-stage pipeline, received an acquisition offer earlier in January from its Zurzuvae (zuranolone) partner Biogen and the company’s board of directors issued a response on 27 January, rejecting the bid. The board also initiated a review of strategic alternatives, which could include a sale of Sage or some other transaction, with the aim of generating a more favorable outcome for the company’s shareholders.
Sage Spurns Biogen, Turns Attention To Strategic Review
Proposed Deal’s Value Seen As Too Low
Sage’s board of directors initiated a search for strategic alternatives, which could include a sale of the company, but the board rejected a buyout bid from Biogen, its partner on the PPD drug Zurzuvae.
More from Deals
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.